Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis
about
sameAs
Biomarkers in Pediatric ARDS: Future DirectionsAcute and subacute idiopathic interstitial pneumoniasThe coagulopathy of acute sepsisPAMPs and DAMPs as triggers for DICCombination therapy with sivelestat and recombinant human soluble thrombomodulin for ARDS and DIC patients.Thrombomodulin in the management of acute cholangitis-induced disseminated intravascular coagulation.Utility of thromboelastography and/or thromboelastometry in adults with sepsis: a systematic review.A thrombomodulin mutation that impairs active protein C generation is detrimental in severe pneumonia-derived gram-negative sepsis (melioidosis).Thrombomodulin contributes to gamma tocotrienol-mediated lethality protection and hematopoietic cell recovery in irradiated mice.Efficacy of thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia: a nonrandomized prospective study.Exogenous carbon monoxide attenuates inflammatory responses in the small intestine of septic mice.Elevated soluble thrombomodulin is associated with organ failure and mortality in children with acute respiratory distress syndrome (ARDS): a prospective observational cohort study.Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysisCan recombinant human thrombomodulin increase survival among patients with severe septic-induced disseminated intravascular coagulation: a single-centre, open-label, randomised controlled trial.Thrombomodulin and the vascular endothelium: insights into functional, regulatory, and therapeutic aspects.The coagulation system in melioidosis: from pathogenesis to new treatment strategies.Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials.Efficacy of recombinant human soluble thrombomodulin for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: a single arm, non-randomized prospective clinical trial.Recombinant human soluble thrombomodulin is active against hemophagocytic lymphohistiocytosis associated with acquired immunodeficiency syndrome.Treating Eyres type IV and V coracoid fracture using the acromion osteotomy approach.Observational study to compare antithrombin and thrombomodulin for disseminated intravascular coagulation.Recombinant human soluble thrombomodulin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study.Thrombomodulin protects against lung damage created by high level of oxygen with large tidal volume mechanical ventilation in rats.Use of recombinant human soluble thrombomodulin in patients with sepsis-induced disseminated intravascular coagulation after intestinal perforation.Early coagulation disorder after allogeneic stem cell transplantation is a strong prognostic factor for transplantation-related mortality, and intervention with recombinant human thrombomodulin improves the outcome: a single-center experience.Involvement of high mobility group box 1 and the therapeutic effect of recombinant thrombomodulin in a mouse model of severe acute respiratory distress syndrome.Thrombin generation mediators and markers in sepsis-associated coagulopathy and their modulation by recombinant thrombomodulin.Treatment of low molecular weight heparin inhibits systemic inflammation and prevents endotoxin-induced acute lung injury in rats.Clinical Impact of Recombinant Soluble Thrombomodulin for Disseminated Intravascular Coagulation Associated with Severe Acute Cholangitis.Association of serum high-mobility group box protein 1 level with outcomes of acute exacerbation of idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia.Recombinant human soluble thrombomodulin improves mortality in patients with sepsis especially for severe coagulopathy: a retrospective study
P2860
Q26744577-ABD35B28-5332-4C92-AEF6-264986FAB207Q26824327-541C017F-B1D5-4392-96D4-4A6A3B6F9AF7Q26826950-8756CD7B-1944-4946-91C2-55622C63B054Q27013790-F3020B24-9568-43F8-BE0A-FB7177921C98Q34155686-DBB0204A-2F66-4BE0-A40E-2111082698CAQ34932581-91105526-E1ED-4193-A1D1-DFD71EBE378FQ35089987-E547276A-9DE1-44C8-B1E5-C23A180C5CF0Q35156788-59FB76D4-2E3D-47C0-A233-A3EF924F0EF0Q35364503-3DDC7978-944D-4636-94DA-5E18C83E005FQ36232373-2273256B-92DB-4AC1-9D6F-1A38CBFE7F05Q36357446-27DB402B-9D98-47F2-94D1-F4E22572EF19Q36424706-94880258-C2DA-41F1-BA1A-9FEE40169A04Q36715005-C0A1DDC1-B87F-4669-A694-83E2B738C005Q37576659-CC2EEC35-6D87-49C0-B31B-1284F49D77EDQ38100652-29D17298-0134-40CF-AE98-BEA593D7DD26Q38222979-E2F1BB1D-2EC6-416C-BEAD-DB78FCB5CCC4Q38670135-ADF891BC-77CD-4606-AB04-D2B4906E2472Q39203095-B8961F81-9CA2-40BA-B57D-6F7AC6E20FF9Q40232358-B3559F2B-A361-4351-8DE9-EBF46D46CCD4Q41117331-AAFDAB2B-31C7-47B9-9B25-62D041C37A94Q41595614-18EC0C66-54FE-465E-8658-4A75E5915050Q41664315-57520365-1038-4785-9478-AF26B10990C6Q41848099-71E2D0E7-E983-4634-990C-2C6F99A18AB1Q43163829-59BA6AEE-2ADD-4879-824E-3DB7F44A36B5Q44696198-C04BF462-AA33-4D99-85DF-01D449A9635EQ45216367-F114F688-47D4-4D86-BE68-EC7B0A8525A9Q46608077-533B337E-0294-443B-B065-4A0213145CA0Q47188763-7E00343B-40AE-4979-8FD4-2E132E383FD8Q52560789-11ADFB55-C265-4CF6-A177-346DA8859833Q55072872-545CECB6-504B-4759-8D12-BC0F1AE70A63Q56518823-8C0DAA8D-7897-4A1F-96D7-D4E1AC5CF1CF
P2860
Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis
description
scientific article published on 01 May 2012
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 2012
@uk
name
Recombinant human soluble thro ...... in patients with severe sepsis
@en
Recombinant human soluble thro ...... in patients with severe sepsis
@nl
type
label
Recombinant human soluble thro ...... in patients with severe sepsis
@en
Recombinant human soluble thro ...... in patients with severe sepsis
@nl
prefLabel
Recombinant human soluble thro ...... in patients with severe sepsis
@en
Recombinant human soluble thro ...... in patients with severe sepsis
@nl
P2093
P1476
Recombinant human soluble thro ...... in patients with severe sepsis
@en
P2093
Hiroshi Ogura
Kazuma Yamakawa
Satoshi Fujimi
Takeshi Shimazu
Takeyuki Kiguchi
Tomoyoshi Mohri
Yasushi Nakamori
Yasuyuki Kuwagata
Yoshihito Ogawa
P304
P356
10.1097/TA.0B013E3182516AB5
P577
2012-05-01T00:00:00Z